ClinicalTrials.gg
CompletedNCT07339735Updated Apr 20, 2026

A Study of LY4064809 in Healthy Adult Participants

A Phase 1 interventional study of LY4064809 Test Formulation and LY4064809 Reference Formulation in Healthy Participants, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to find out how much LY4064809 gets into the blood stream and how long it takes the body to get rid of it when it is given as two formulations. For each participant, the study will last about nine weeks. Participants will remain in the clinical research center for about one month.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are healthy as determined by medical evaluation, including medical history, physical examination, vital signs, and (ECG) at screening and admission.
  • Have clinical laboratory test results within the normal range
  • Have normal blood pressure and pulse rate or not
  • Have a within the range 18 to 32 kg/m2
  • Participants assigned male at birth or assigned female at birth who are not of

Exclusion criteria

Exclusion Criteria:

  • History or presence of any of the following conditions, deemed by the investigator (or designee):

    • metabolic disease, including congenital non-hemolytic hyperbilirubinemia, for example, Gilbert syndrome
    • bile duct disease, including removal of the gall bladder
    • digestive system disease
    • blood disease
    • disease of the nervous system
    • significant history of, or presence of, liver disease, including any abnormal liver function tests
    • heart disease
  • Have an abnormal (ECG) at screening or admission
  • History of a major surgical procedure within 30 days prior to screening
  • Diagnosed or treated cancer within 5 years prior to screening, with the exception of the following cancers cured through treatment: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and in situ carcinoma of the cervix cured through surgery

    • Clinically significant history of multiple or severe drug reactions or drug allergies, as determined by the investigator
  • Have used or plan to use medication within 14 days prior to admission, or plan to use during the study with the exception of acetaminophen
  • Have creatinine lab clearance less than 90mL/min calculated using the Cockroft-Gault equation at screening
  • Have a positive surface antigen (HBsAg), virus antibody or 1 and 2 antibody results at the screening visit
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    LY4064809 Test

    LY4064809 test (Phase 3 formulation) formulation administered orally in one of two periods.

    Drug: LY4064809 Test Formulation · Drug: LY4064809 Reference Formulation

  • Experimental
    LY4064809 Reference

    LY4064809 reference (Phase 1 formulation) formulation administered orally in one of two periods.

    Drug: LY4064809 Test Formulation · Drug: LY4064809 Reference Formulation

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4064809

    PK: Cmax of LY4064809

    Time frame: Predose on Day 1 Through Day 28

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of LY4064809

    PK: AUC of LY4064809

    Time frame: Predose on Day 1 Through Day 28

07

Study locations

1 site
  • Fortrea Clinical Research Unit Inc. - Madison
    Madison, Wisconsin 53704-2526, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Mar 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 14, 2026
StartActual
Jan 12, 2026
Primary completionActual
Mar 19, 2026
CompletionActual
Mar 19, 2026
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07339735
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Jan 12, 2026
Primary completion
Mar 19, 2026
Completion
Mar 19, 2026
Last update
Apr 20, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STX-478

Start the discussion